Breast Cancer Treatment Protocols: Systematic Review of the Last 35 Years
- Authors
-
-
Thais Ligiero Braga
Military Hospital Marcilio Dias, Nuclear Medicine Division, Rio de Janeiro, Brazil -
Filipe Leal Portilho
Brazilian Nuclear Energy Commssion, Nuclear Enginerring Institute, Rio de Janeiro, Brazil -
Ralph Santos-Oliveira
Brazilian Association of Radiopharmacy, Presidency, Rio de Janeiro, Brazil
-
- Keywords:
- Breast cancer, protocols, systematic review.
- Abstract
-
Breast cancer is the main leading type of cancer for women around the world and is responsible for 522,000 deaths per year worldwide. In order to reduce this number, clinicians and researchers are always looking for new strategies and protocols. However, the treatment for breast cancer is challenging and requires as much information as possible. To this end, we conducted a review of all protocols used for breast cancer treatment in the last 35 years with the objective to help clinicians to choose the best treatment possible available in their region. Many of the protocols are international references, and for that reason have been used in many countries like USA and Europe. The data, depicted in tables, may be helpful for clinicians worldwide and researchers to better understand the evolution of breast cancer protocols such as helping make daily routine decisions.
- References
-
Miller DK, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66: 271-289. https://doi.org/10.3322/caac.21349
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66(1): 7-30. https://doi.org/10.3322/caac.21332
Scalia-Wilbur J, et al. Breast Cancer Risk Assessment: Moving Beyond BRCA 1 and 2. Semin Radiat Oncol 2016; 26(1): 3-8. https://doi.org/10.1016/j.semradonc.2015.09.004
Tang Y, et al. Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer. Clin Breast Cancer 2016; pii: S1526-8209(16)30108-2.
Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti–HER-2 therapy and personalized medicine. Oncologist 2009; 14: 320-368. https://doi.org/10.1634/theoncologist.2008-0230
Abramovitz M, et al. Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer. Clin Breast Cancer 2016; pii: S1526-8209(16)30146-X.
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434. https://doi.org/10.1158/1078-0432.CCR-06-3045
Bernier J, et al. Surgery and radiation therapy of triplenegative breast cancers: From biology to clinics. Breast 2016; 28: 148-55. https://doi.org/10.1016/j.breast.2016.05.014
Verdecchia A, De Angelis G, Capocaccia R. Estimation and projections of cancer prevalence from cancer registry data. Stat Med 2002; 21: 3511-3526. https://doi.org/10.1002/sim.1304
DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014; 64: 252-271. https://doi.org/10.3322/caac.21235
Bhargava A, Du XL. Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer. Cancer 2009; 115: 2999-3008. https://doi.org/10.1002/cncr.24363
McGuire KP, Santillan AA, Kaur P, et al. Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol 2009; 16: 2682-2690. https://doi.org/10.1245/s10434-009-0635-x
Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg 2015; 150: 9-16. https://doi.org/10.1001/jamasurg.2014.2895
Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784-1792. https://doi.org/10.1056/NEJMoa050518
Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol 2016; 34: 611-635. https://doi.org/10.1200/JCO.2015.64.3809
Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 2012; 104: 386-405. https://doi.org/10.1093/jnci/djr541
- Downloads
- Published
- 2017-12-28
- Issue
- Vol. 6 No. 2 (2017)
- Section
- Articles
How to Cite
Similar Articles
- Vladimir Zaichick, Sofia Zaichick, Sinclair Wynchank, Intracellular Zinc Excess as One of the Main Factors in the Etiology of Prostate Cancer , Journal of Analytical Oncology: Vol. 5 No. 3 (2016)
- Kenji Ina, Ryuichi Furuta, Takae Kataoka, Sayaka Sugiura, Satoshi Kayukawa, Takayuki Kanamori, Takaki Kikuchi, Megumi Kabeya, Satoshi Hibi , Shu Yuasa , Adverse Effects of Bevacizumab During Treatment for Metastatic Colorectal Cancer , Journal of Analytical Oncology: Vol. 4 No. 1 (2015)
- Tatiana Levkovich, Theofilos Poutahidis, Kelsey Cappelle, Mark B. Smith, Allison Perrotta, Eric J. Alm , Susan E. Erdman , ‘Hygienic’ Lymphocytes Convey Increased Cancer Risk , Journal of Analytical Oncology: Vol. 3 No. 3 (2014)
- Arunima Ghosh, Karlena Lara-Otero, Marston W. Linehan , Maria J. Merino , Can Mutations in the BAP1 Gene be Detected by Immunohisto-chemistry in Hereditary Kidney Cancers? , Journal of Analytical Oncology: Vol. 3 No. 3 (2014)
- D.A. Tzerkovsky, A.N. Mazurenko, F.F. Borychevsky, D.V. Shashkouski, Radiodynamic Therapy with Photosensitizers: Mini-Review of Experimental and Clinical Studies , Journal of Analytical Oncology: Vol. 11 (2022)
- Anshuma Bansal, Gandharv Vyas, Neeru Bedi, Aditya Singla, Sunigdha Charry, Gurpreet Singh, Vinod Kumar Dangwal, Raja Paramjeet Singh, Bladder Filling Variation in Cancer Cervix Patients Treated by Image Guided Radiation Therapy , Journal of Analytical Oncology: Vol. 14 (2025)
- Autumn Smith, Emily Elias, Gerald M. Higa, Evolution of Cancer, Adaptive Immunity, and Immunotherapy , Journal of Analytical Oncology: Vol. 8 (2019)
- Abigail Ruiz de Lobera, Aitziber Buqué, Alberto Muñoz, Sergio Carrera, Aintzane Sancho, Itziar Rubio, Eddy I. Gutierrez, Mikel Arruti, Inés Marrodán, Guillermo López-Vivanco, Bevacizumab in Combination with FOLFIRI in the First-Line Treatment of Patients with Advanced Colorectal Cancer: A Single-Institution Experience , Journal of Analytical Oncology: Vol. 3 No. 1 (2014)
- Javier Garde Noguera, Elena Evgenyeva, Mireia Gil Raga, Asunción Juárez Marroquí, Juan Manuel Gasent Blesa, Juan Laforga, Laia Bernet, Mónica Clemente Císcar, Carlos Camps Herrero, Antonio Llombart Cussac, Role of Primary Tumour Resection and Addition of Bevacizumab to Chemotherapy in the Management of Advanced Colorectal Cancer with Inoperable Metastasis: A Retrospective Analysis , Journal of Analytical Oncology: Vol. 2 No. 4 (2013)
- Kenji Ina, Ryuichi Furuta, Tomoko Nishio, Satoshi Kayukawa, Takae Kataoka, Haruhito Totani, Takashi Kanamori, Takaki Kikuchi, Shun Umeda, Tamio Fujita, Pathological Complete Response Induced by the Combination Therapy of Gemcitabine and 24-h Infusion of Cisplatin in Two Cases Initially Diagnosed as Node-Positive Advanced Urothelial Carcinomas , Journal of Analytical Oncology: Vol. 2 No. 4 (2013)
You may also start an advanced similarity search for this article.
Most read articles by the same author(s)
- Augusto Bordim, Beatriz Ferreira de Carvalho Patricio, Michelle Álvares Sarcinelli, Marta de Souza Albernaz, Ralph Santos-Oliveira, Nanoradiopharmaceuticals: Development oF Labeling Process for Polymeric Nanoparticles , Journal of Analytical Oncology: Vol. 2 No. 1 (2013)
- Fagner Santos do Carmo, Marta de Souza Albernaz , Ralph Santos-Oliveira, Radiopeptides Analogues of Somatostatin Used for the Treatment of Neuroendocrine Tumors - Literature Review , Journal of Analytical Oncology: Vol. 3 No. 1 (2014)